Measuring P2X4 Receptors in Blood as a Test for ALS
Tests whether P2X4 receptors in blood cells can help detect ALS in adults.
Plain-language title generated from the registry record
Registry title: Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
Key facts
- Where
- Bordeaux, FranceSee the site
Where in France
- Hopital PellegrinBordeaux, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT07091799
- Record updated
- 21 January 2026
- Original description
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 purinergic pathway that appears to be involved in the pathogenesis of ALS. Our goal is to verify these results at the human level in order to have a proof of concept of P2X4's role as a biomarker of the disease.Read full original descriptionShow less
Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 purinergic pathway that appears to be involved in the pathogenesis of ALS. Our goal is to verify these results at the human level in order to have a proof of concept of P2X4's role as a biomarker of the disease.
Inclusion: For ALS group: Person presenting a probable or confirmed diagnosis of ALS according to the criteria of EI Escorial; Adult; Person affiliated or beneficiary of a social security scheme; Free, informed and written consent signed by the participant or by a third person (in case of physical incapacity of the participant), after information on the study.
Exclusion: People undergoing immunosuppressive or corticosteroid treatments; Participation in a research protocol with an experimental treatment; People placed under guardianship, curatorship or legal protection; For healthy volunteer, people directly related to the patient (siblings, descendants and ancestry).